Everest Medicines Limited (HKG:1952)
50.45
-6.90 (-12.03%)
Jun 13, 2025, 4:08 PM HKT
Everest Medicines Revenue
In the year 2024, Everest Medicines had annual revenue of 706.68M CNY with 461.16% growth. Everest Medicines had revenue of 405.16M in the half year ending December 31, 2024, with 3,348.77% growth.
Revenue
706.68M CNY
Revenue Growth
+461.16%
P/S Ratio
21.77
Revenue / Employee
1.06M CNY
Employees
665
Market Cap
16.37B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.53B |
Hansoh Pharmaceutical Group Company | 13.05B |
Innovent Biologics | 10.03B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
CSPC Pharmaceutical Group | 28.99B |
Sino Biopharmaceutical | 30.72B |
Akeso | 2.26B |
Everest Medicines News
- 2 months ago - AI-powered Cancer Vaccine In The Works - Benzinga
- 10 months ago - Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Benzinga